Use este identificador para citar ou linkar para este item: https://observatorio.fm.usp.br/handle/OPI/21965
Título: Decreased glycolytic metabolism in non-compaction cardiomyopathy by F-18-fluoro-2-deoxyglucose positron emission tomography: new insights into pathophysiological mechanisms and clinical implications
Autor(es): MELO, Marcelo Dantas Tavares deGIORGI, Maria Clementina PintoASSUNCAO JR., Antonildes NascimentoDANTAS JR., Roberto NeryARAUJO FILHO, Jose de ArimateiaPARGA FILHO, Jose RodriguesBIERRENBACH, Ana Luiza de SouzaLIMA, Camila Rocon deSOARES JR., JoseMENEGUETTI, Jose ClaudioMADY, CharlesHAJJAR, Ludhmila AbrahaoKALIL FILHO, RobertoBOCCHI, Edimar AlcidesSALEMI, Vera Maria Cury
Parte de: EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, v.18, n.8, p.915-921, 2017
Resumo: Aims The pathophysiological mechanisms of left ventricular non-compaction cardiomyopathy (LVNC) remain controversial. This study performed combined F-18-fluoro-2-deoxyglucose dynamic positron emission tomography (FDG-PET) and 99mTc-sestamibi single-photon emission computed tomography (SPECT) studies to evaluate myocardial glucose metabolism and perfusion in patients with LVNC and their clinical implications. Methods and results Thirty patients (41 +/- 12 years, 53% male) with LVNC, diagnosed by cardiovascular magnetic resonance (CMR) criteria, and eight age-matched healthy controls (42 +/- 12 years, 50% male) were prospectively recruited to undergo FDG-PET with measurement of the myocardial glucose uptake rate (MGU) and SPECT to investigate perfusion-metabolism patterns. Patients with LVNC had lower global MGU compared with that in controls (36.9 +/- 8.8 vs. 44.6 +/- 5.4 mu mol/min/100 g, respectively, P = 0.02). Of 17 LV segments, MGU levels were significantly reduced in 8, and also a reduction was observed when compacted segments from LVNC were compared with the segments from control subjects (P < 0.001). Perfusion defects were also found in 15 (50%) patients (45 LV segments: 64.4% match, and 35.6% mismatch perfusion-metabolism pattern). Univariate and multivariate analyses showed that beta-blocker therapy was associated with increased MGU (beta coefficient = 10.1, P = 0.008). Moreover, a gradual increase occurred in MGU across the beta-blocker dose groups (P for trend = 0.01). Conclusion The reduction of MGU documented by FDG-PET in LVNC supports the hypothesis that a cellular metabolic pathway may play a role in the pathophysiology of LVNC. The beneficial effect of beta-blocker mediating myocardial.
Aparece nas coleções:

Artigos e Materiais de Revistas Científicas - FM/MCP
Departamento de Cardio-Pneumologia - FM/MCP

Artigos e Materiais de Revistas Científicas - FM/MOG
Departamento de Obstetrícia e Ginecologia - FM/MOG

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - LIM/11
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação

Artigos e Materiais de Revistas Científicas - LIM/58
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular


Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
art_MELO_Decreased_glycolytic_metabolism_in_noncompaction_cardiomyopathy_by_F18fluoro2deoxyglucose_2017.PDF
  Restricted Access
publishedVersion (English)408.08 kBAdobe PDFVisualizar/Abrir    Solicitar uma cópia

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.